Good morning, everyone, and thank you for your attendance today. My name is Cameron Sinclair, Head of Investor Relations.

I'm joined today by Adam Hall, our Group CEO, and Alistair Gray, our Group CFO. Before commencing, I'd like to draw your attention to the disclaimer on page 2 of the presentation.

The results are expressed in Australian dollars unless otherwise noted, and the presentation refers to both statutory and underlying results. The commentary this morning is predominantly based on our underlying results, and a reconciliation is included in the appendix.

I'll now hand over to Adam to take you through today's presentation.

Thanks, Cameron. Good morning, everyone.

There are 3 messages to take away from today's results. First, we delivered on our commitments while completing a major phase of investment.

Revenue increased 9.9% to $13.5 billion, and underlying EBITDA increased 5% to $614 million, both within guidance. We have also completed our multi-year $360 million distribution center renewal program, with all facilities now in operation.

Second, each division has clear growth opportunities in FY27 across Symbion and Healthcare Distribution, Retail Pharmacy Brands, Medical Technology, and Animal Care. We have identified initiatives that support continued earnings growth.

Each of these initiatives is underpinned by 2 common macro themes: strong underlying growth in care for an aging human and pet population, and EBOS's competitive advantages of scale and sector leadership. As we laid out at Investor Day, 85% of our EBITDA is derived from businesses where we are number 1 or number 2 in our sector.

Third, we are not pausing. We continue to improve the portfolio with 2 great bolt-on acquisitions in the last 6 months, and the capacity for more.

You may recall over the last few years, we've deliberately shifted the portfolio towards higher growth, higher return businesses. In FY26, we continue this theme with 8 bolt-on acquisitions that improve the quality of our portfolio.

Now, importantly, with about 30% lower capital requirements going forward, we have greater flexibility to continue investing in these attractive growth opportunities. Taken together, we enter FY27 with earnings momentum, a completed investment cycle, and additional capacity to deploy capital.

The team have confidence in their ability to continue creating value for shareholders. Let me turn to slide 4 and our financial guidance and metrics.

At the start of the year, we set clear financial targets across EBITDA, capital expenditure, depreciation and amortization, financing costs, and leverage. We've delivered on these as a group and in each division.

Despite fuel costs and foreign exchange headwinds during the year, we delivered against our stated guidance ranges, noting that EBITDA guidance was revised in April following the disruption in the Middle East. Just as importantly, we continue to make progress against the strategic priorities we outlined at our Investor Day.

In Symbion and Healthcare Distribution, we've now completed the distribution center renewal program, with all facilities operational. In Retail Pharmacy Brands, we expanded the network with the acquisition of MedAdvisor, which strengthened healthcare services capabilities, and continued to improve digital transactions, where we're up 30%, and our own brand performance.

In Medical Technology, we broadened our therapy and product portfolio with 18 new supply partnerships, and we grew the business both organically and through targeted acquisitions. In Animal Care, we expanded innovation, manufacturing, and product development, including Kiwi Kitchens' triumphant return to the US market.

The next slide explains the key earnings movement during the year. You can see here that underlying EBITDA increased by 5%, despite approximately $22 million of fuel and foreign exchange headwinds.

Importantly, the underlying performance of the business remained solid, generating $50 million more in EBITDA. The fuel headwinds we called out during the half were contained through operational improvements, fuel levy pass-through, and active contract management.

The impact was about $5 million, which was at the lower end of our previous expectations. Also during the half, you'll have seen the Australian dollar strengthened against many currencies and hit a 13-year high against the New Zealand dollar.

This had a meaningful effect on translated earnings for the group and purchasing costs predominantly within the Medical Technology division. Across the portfolio, Healthcare grew EBITDA by a net 3.2%, and Animal Care by a net 11.6%.

While external factors affected the reported growth rate, they didn't change our underlying trajectory, and that gives us confidence as we enter FY27. On the next slide, I'd like to highlight one of the most significant strategic milestones we achieved during the year.

With the DC renewal program, I want to pay tribute to the teams across the business, and particularly the Symbion healthcare and distribution division, who've successfully brought this program to completion and done so seamlessly. Our $360 million distribution center renewal program is the largest infrastructure investment in EBOS's history.

Think of this as a long-term investment in the capability, capacity, and efficiency of our network, positioning us to serve the need for medicines across Australia and New Zealand for years to come. Just as importantly, the focus now shifts from investment to benefits.

We're already seeing productivity gains at Kemps Creek, with the site currently operating around 20% more productively than Greystanes, the facility it replaced. Just to give you a sense of magnitude of what Kemps Creek does, every morning, it converts about 16,000 SKU lines in storage to 8,000 daily customized totes and then delivers in hours to pharmacies and hospitals across New South Wales.

There's more productivity opportunity ahead. We continue to target a 30% productivity uplift by the end of FY27, and I was glad many of you got a chance to meet the Kemps Creek team at the recent Investor Day and see this opportunity up close.

The completion of this program also materially lowers our capital requirements, and capex is expected to normalize around $100 million in FY27. Now, that matters because lower capex supports stronger free cash flow, improving returns, and greater balance sheet flexibility.

A good example of that flexibility is in contract logistics. Over several years, we've invested in building a national healthcare logistics network.

That capability is now supporting customer wins, share gains, and double-digit GOR growth. I'm delighted that the Perth HCL facility is now up and serving our customers.

With the distribution centers now complete and operational, we close the chapter on this program, and we look ahead. Speaking of looking ahead, the final point I'd like to touch on before moving into the divisions is M&A.

On the next slide, you can see that disciplined capital allocation remains a core part of the EBOS strategy. During FY26, we deployed approximately $121 million across 8 bolt-on acquisitions that strengthened capability, expanded market positions, and increased our participation in attractive growth categories.

Now, in the last 6 months, the 2 acquisitions were Paringa Pet Foods and Catalyst. Paringa expands our presence in premium pet nutrition and gives us exposure to the fast-growing fresh and chilled pet food category.

We have a great track record of bringing our strong brands like Black Hawk and Vitapet into new formats, and this continues that theme. Catalyst is another great example of bolt-on M&A in action.

We had an existing supply relationship that was very strong, and with the benefit of this Catalyst acquisition, it's extended that into new markets across Southeast Asia and Hong Kong, particularly in aesthetics and reconstruction. What's pleasing is that these acquisitions are consistent with our strategy of higher growth, higher return markets and are expected to be both EBITDA and EPS accretive.

Looking ahead, our approach continues unchanged. We will stay disciplined, but where we see privileged access to attractive opportunities supported by our market positions, relationships, and balance sheet capacity, we have about $150 million of additional capacity to support our bolt-on M&A agenda.

Let me now take you through the divisional highlights and financial performance. On slide 9, you can see that Healthcare delivered another resilient result.

Revenue increased 8.5% to $12.6 billion, and EBITDA increased 3.2% to $516 million, despite fuel and foreign exchange headwinds. Now, this result was supported by growth across community pharmacy, hospital medicines, medical technology, and contract logistics.

As I mentioned, this result is underpinned by an aging population, which increases healthcare demand, growth in specialty and high-value medicines, and a larger role for pharmacy in primary care. Sales of high-value medicines and GLP-1 demand also continued to grow at double digits.

While FY26 was an important year of execution, we believe each of our divisions are well positioned for the next phase of growth. Let's start with Symbion and Healthcare Distribution.

Here, we delivered another solid result while completing a significant period of operational change, as I just mentioned. While the team has successfully executed multiple site transitions, they continued to grow the business.

What you may not realize is that Symbion now serves 1 million units a day to Australians, the vast majority through our automated Eastern Seaboard facilities. Within Community Pharmacy, revenue increased 10.2%, and GOR increased 4.3%, supported by continued growth in GLP-1s and other high-value medicines.

Margin pressure remained a feature of the market, but GOR margins were stable across the second half at 8.6%. Looking forward, increased CSO funding should provide some support, although that needs to be netted against the medicine tiering changes, as well as continued competitive conditions.

Hospital medicines, consumables, and other also delivered growth, supported by record hospital sales, expansion in aged care and healthcare channels, and continued momentum in medical consumables. Contract logistics was once again a standout performer.

Our GOR increased 13.1%, reflecting customer growth and the benefits of the investments we've made over several years in our healthcare logistics capability. The priorities in FY27 are straightforward: increase utilization, improve productivity, and leverage our national footprint within contract logistics.

Moving now to Retail Pharmacy Brands. Here, we've had another strong year, where we continued to expand both our scale and capability.

Network sales reached almost $2.9 billion, supported by like-for-like growth of 7.6% across the TerryWhite Chemmart network and dispensary sales growth of 8.5%. Importantly, this growth reflects the quality of the network and the performance of existing stores, not just network expansion.

Total network stores increased to 780, driven by the addition of MedAdvisor and continued growth across our other banner groups, including Sinocare. Healthcare services remained a key differentiator.

During FY26, care clinics delivered more than 1.2 million health services, reinforcing the network's leading position in pharmacy-delivered healthcare. We're also seeing encouraging progress across our own brands, digital engagement, and retail media.

The myTWC app is a great demonstration of this, with the app processing 1.7 million transactions. Now, that's up 37% on the prior year.

Network sales of our own brand increased 11% during the year, and these initiatives are helping broaden the earnings base for both the network and our pharmacy partners. Looking ahead, our focus remains on improving store margins, increasing health service participation, growing digital engagement, and expanding our own brand penetration.

I turn now to Medical Technology. Here, revenue increased 5.5%, or 8.4% on a constant currency basis, supported by a combination of organic growth and acquisitions.

Growth was broad-based across the portfolio and reflected higher procedure volumes, therapy expansion, and ongoing innovation. Across ANZ, we saw strong growth in neurosurgery, neurovascular intervention, and urology.

In Southeast Asia and Hong Kong, growth continued across spine, orthopedics, cardiology, and ophthalmology, partly offset by softer capital equipment activity compared with a strong prior year. Biologics remains one of our most attractive growth opportunities.

During the year, we expanded solution development activity and extended into adjacent procedures, which creates additional pathways for growth. Across MedTech, we also completed 4 acquisitions that expanded coverage across oncology, orthopedics, plastics, and aesthetics.

These acquisitions continue our strategy of building capability in attractive growth markets. Looking forward, we see significant opportunities to expand therapy participation, increase biologics exposure, and selectively grow across Southeast Asia.

Now let me turn to Animal Care, which once again delivered a strong result and continues to outperform many of the markets in which it operates. Revenue increased 34.6% to $907 million, and EBITDA increased 11.6% to $138 million.

The result was supported by the SVS acquisition, but also by continued growth within Lyppard and ongoing share gains across branded products. In fact, branded revenue increased 6.7%, supported by innovation, premiumization, and new product development.

On the next slide, you can see the clear linkage between our manufacturing capability and new product development across our hero brands, driving the organic growth within the branded portfolio. Wholesale performance also continued to benefit from greater scale and customer growth, with SVS growth accelerating under EBOS stewardship.

GOR increased 13.1%, showing the quality of growth across the portfolio, and margins were arithmetically affected by the addition of the lower margin wholesale business, SVS, but the segment continued to deliver strong earnings growth. Our strategic focus during FY26 was increasing our participation in the premium pet nutrition categories, and the acquisitions of Next Generation Pet Foods and Paringa did this by expanding our manufacturing capability and our exposure to higher growth segments, including fresh and chilled pet food and air and freeze-dried treats.

As we move into FY27, our Animal Care priorities remain centered on innovation, vet channel growth, premium nutrition, and extracting value from our recent acquisitions. I'll now hand over to Alistair, who's going to take you through the key movements in the group financials.

Thank you, Adam. I will cover the details in the next few slides, but at a headline level, FY26 was another solid result and consistent with the guidance we provided to the market.

Revenue increased 9.9%, and underlying EBITDA was up 5% to $614 million, with that growth delivered despite the macroeconomic headwinds Adam mentioned earlier. This resilient growth speaks to the ongoing strong demand for care needed for an aging human and pet population, and EBOS's competitive advantage of scale and sector leadership.

Underlying NPAT was $250 million, reflecting the completion of the DC renewal program investments. At a statutory level, EBITDA was up 7.8%, and NPAT was up 4.7%.

Importantly, the balance sheet remains in good shape. Leverage finished the year at 2.1 times, within our target range, and the board has maintained the final dividend at 61.5 cents per share.

Now turning to earnings performance in more detail. As previously mentioned, revenue grew strongly at 9.9%, driven by growth in both Healthcare and Animal Care, including the positive contribution from accretive bolt-on acquisitions.

Underlying EBITDA increased 5% to $614 million, despite fuel and foreign exchange headwinds. This result demonstrates the resilience, diversity, and strength of positions across the portfolio.

EBITDA margin improved in the second half, ending the full year slightly down at 4.6%, largely due to the product mix and competitive dynamics in Community Pharmacy. Below EBITDA, the movements are consistent with guidance and reflect the completion of the 4-year capital investment cycle.

On a statutory basis, EBITDA and NPAT growth was stronger than underlying, with lower one-off costs in FY26 than in FY25. Consistent with the communication at our first-half results, restructuring and site transition costs reduced in the second half.

These results are as expected, and the renewed DC network provides the capacity and capability to support future growth. Importantly, as the capital investment cycle is now complete, from FY27, capex drops materially, and the focus shifts to increasing utilization, productivity, and cash generated from those assets.

In summary, the FY26 result demonstrates that the underlying growth fundamentals remain strong across the group, and with the infrastructure upgrades now in place, we're increasingly well positioned to turn that growth into stronger cash flow and better returns. Moving to capital allocation.

Our framework remains unchanged and is centered around a disciplined approach of capital across 4 priorities: preserving a strong balance sheet, maintaining operational resilience, delivering sustainable shareholder dividends, and investing in attractive growth opportunities. In FY26, we allocated $145 million to capital expenditure, $121 million to bolt-on acquisitions, and returned $128 million to shareholders by the way of dividends.

Importantly, given the strength of cash generated, we've been able to maintain dividends through the peak capital investment cycle while also investing in accretive growth opportunities, including programmatic bolt-on acquisitions. That said, as capex normalizes in FY27, we expect greater flexibility and capacity to deploy capital into attractive growth opportunities and improve returns.

Now turning to the balance sheet. Leverage finished FY26 at 2.1 times, comfortably within our target range of 1.7 to 2.3 times.

Given the seasonal nature of our working capital and cash flows, like prior years, we expect leverage to increase modestly in the first half of FY27 before easing in the second half. This provides approximately $150 million of available capacity to invest through the year up to the leverage of 2.3 times.

Moreover, our debt position remains strong, with $726 million of undrawn committed facilities and a weighted average debt maturity of more than 3 years. With lower capital expenditure, stronger cash flow, and continued earnings growth, we are well placed to steadily reduce leverage whilst continuing to fund growth investments.

I will now step through the cash flow results. Net working capital remained well controlled, increasing by just $7 million despite 10% revenue growth, while cash conversion days were stable at an average of 20 days.

This reflects a disciplined focus on working capital, as well as the favorable timing of year-end payments and receipts. Reported free cash flow was $204 million, representing the final year of elevated capex and site transition costs related to the DC renewal program.

On a normalized basis, our reported free cash flow improved slightly compared to the prior year. With the capital investment cycle now complete, capex is expected to fall materially to approximately $100 million in FY27, compared to $145 million in FY26.

That lower capex should drive a meaningful improvement in free cash flow in FY27. Important as it enables additional investment to drive growth.

I'll now hand back to Adam, who will share our perspective on the year ahead.

Thanks, Alistair. When I look ahead to FY27, across every division, we have clear operational priorities focused on growth, productivity, and returns.

In Symbion and Healthcare Distribution, our focus is on putting our new capacity to work. In Retail Pharmacy Brands, we drive store dollar growth.

In Medical Technology, we expand our scope and reach. Finally, in Animal Care, our focus is on new product development and customer momentum.

Collectively, these initiatives support our expectation of delivering mid-single-digit EBITDA growth, as we laid out at Investor Day in April. Importantly, FY27 is more than earnings growth.

Our multi-year investment cycle is complete. Capital expenditure since the 30th of June has dropped to approximately $100 million, well below the FY26 levels, which in turn supports stronger free cash flows and improving returns.

Depreciation and financing cost growth will remain elevated as we annualize recent investments, particularly in the first half of FY27. The more important point is the cycle's complete, the assets are in place, and increasingly are being put to work.

I want to share with you this final slide to bring together what we've tried to communicate through today's presentation. As we said at Investor Day, EBOS is very different than the business that we had 5 years ago.

We've increased our exposure to higher growth, higher return businesses, and today, more than 70% of group EBITDA comes from those high-growth businesses, including Animal Care, Medical Technology, and Retail Pharmacy Brands, alongside platforms such as Contract Logistics and Medical Consumables. Our resilience is born of our market position, with around 85% of group EBITDA coming from businesses ranked number 1 or number 2 in their sectors, and that gives us scale, customer relevance, and a strong competitive base.

Importantly, we now move into the next phase with a completed investment cycle, stronger free cash flow prospects, and additional capacity to invest, which will drive returns despite cost pressures and competitive dynamics. The messages to take away from today are simple: we've delivered on our commitments, our investment cycle is complete, we are excited to continue driving value for shareholders.

I want to thank you for listening this morning, and I also want to thank our teams across Australia, New Zealand, Southeast Asia, and Hong Kong for everything they've delivered through FY26. I'm now going to hand back to the operator, who's going to open the call for Q&A.

Thank you.

Good morning. Just wondering if you could please give us a split of FY26 EBITDA growth between kind of organic and inorganic for the group overall, and then for the 2 segments.

Then if maybe just turning to the guidance, if you could comment on how much of the 5% EBITDA growth at the midpoint for '27 is driven by acquisitions and how much is organic? Then which segments are you expecting to deliver the lion's share of the organic EBITDA growth in FY27, please?

Thank you.

Yeah. Stephen, thanks very much for the question.

I'm going to start with the second part, and Alistair going to jump in as needed. When we look ahead and provide that guidance of the $635 to $655 for FY27, we're incorporating in that all the businesses that we have today.

We're not assuming any acquisitions are included in that. I have to say, we're pretty excited for contributions from all of our divisions, roughly in proportion to how we indicated at Investor Day, with the high-growth divisions of MedTech, Animal Care, and RPB really coming to the fore.

Just a reminder, the assets that we've got there to put to work is Australia's largest dog food brand, Australia's largest pharmacy network, and Southeast Asia and Australia's largest independent medical distributor. We've got plenty of market position to find opportunities during FY27.

If I now come back to your question on FY26, I think you're referring to the first substantive chart that we have in the deck. You can see there that we've added $50 million of EBITDA in to the group.

Now, across the last 10 years, we've grown at about 10% and roughly equally between organic and inorganic. In that $50 million, I think it's probably slightly skewed to inorganic.

I think one thing we've been pretty heartened by is the synergistic nature of many of the transactions. For example, SVS was a great business, growing at a fair clip when we bought it, but growth has really accelerated under our stewardship, which we're really pleased by.

Alistair, would you add anything to those comments?

No, I think you've covered it well, Adam. Stephen, it's very consistent with what we outlined at the Investor Day.

If you're looking for a sort of segmental view of growth into FY27, I'd use that as the basis.

Can I just clarify, though? When we're talking about sort of 5% year-on-year EBITDA growth, you've obviously made acquisitions during FY26, and there'll be some annualization of those acquisitions.

That's really what I'm trying to get at, rather than future acquisitions, how much of the 5% growth is driven by acquisitions you've already made in the FY26 year, partway through the year, and how much is driven by organic growth?

Stephen, it's tough for us to give the split because a lot of them are very synergistic. The EBITDA that we've bought might be significantly higher in our hands given the ability to extract value with our existing businesses.

I think we're comfortable with the guidance we've provided.

Potentially, the only other color I would add, Stephen, is clearly there's a lot of moving parts in the group and informing guidance. It's probably important to note that we have considered a number of, I guess, reasonably possible outcomes as they relate to FX and fuel in forming that guidance range as well.

Okay. No, thanks, Alistair.

Second question, also on the guidance, really 2 parts. Just following up on your comment there, Alistair, on fuel cost.

At the low end of the range, are you assuming that fuel costs remain at current levels for the rest of the year? Perhaps at the top end of the range, you've assumed they come down?

Some sense of the assumptions or providing what's a reasonably wide range. Are you taking a worst-case outcome at the low end?

Then have you assumed mitigation of fuel costs in the numbers you provided?

Thanks, Stephen. That's question number 3 and 4, but that's okay.

We're not counting for friends. Alistair, do you want to start on the fuel cost and then the mitigation?

Absolutely. To talk about fuel holistically, we did come out with an update to our guidance in April as a result of the conflict in the Middle East, and at that point called out a $5 to $10 million impact across the 4 months.

Of course, at that point, as now, it's actually difficult to predict the outcome and where fuel prices may track in the market. I think what's been pleasing through the 4 months of FY26 has been the team's ability to mitigate these costs, both through operational improvements and pricing actions taken through that period.

I would say that the 5% for the 4 months is fairly representative of a run rate, noting that fuel prices are currently lower than the average that they were from that 5 months. Yes, at the low end, we have assumed an improvement in fuel prices, and at the top end, we've assumed a worsening.

Thanks, Stephen.

Oh, good morning, team. Just wondering, in the Healthcare division—

Hey, Adrian.

—hey, how you going? In the Healthcare division, when we look at page 27 or slide 27, I'm just wondering if you can help bridge for us.

I think the New Zealand and Southeast Asia revenue was up 10%, but the EBITDA is down 10. Can you just give us a bit more detail what's going on there?

Absolutely, Adrian. It's a fair question.

I'm going to start and Alistair going to chime in. So 2 different pressures here in terms of firstly forex, and then the Southeast Asian capital items.

I know that there was a lot going on in last year's full-year announcement, but we did point to the second half of FY25 having an absolutely outstanding half in terms of capital items sales in Southeast Asia. If you think of that as being well above the norm, and then the number of capital items in the second half of FY26 probably slightly below norms for Southeast Asia.

That plays into it. Also, with the Australian dollar at 13-years high against the New Zealand dollar, that has a big influence on our New Zealand earnings.

Alistair, would you add to that

in

Adrian's question?

Yeah. In terms of the drivers of the EBITDA, they're the 2 2 large forces at play.

Just to put into context the capital sales, perhaps, in the second half, capital sales were more than double in FY25 than the prior corresponding year, and FY26 was more akin to FY24. That did have a material impact.

Then, as Adam called, FX is clearly at an unusual high. I would view, absent not being certain of where FX may go, to be temporary factors, Adrian.

There's nothing underlying or systemic in the outcome. Then the second— —sorry.

Go on, Adrian. Oh,

can I just tidy this little bit up? In constant currency terms, which you have sort of introduced for this part, do you have a sense of what the EBITDA would have been, or would it have been closer to—I think you said constant currency was more like 8% growth, wasn't it?

I know that's for the

MedTech, but

I know that's for the division, including Australia. What would be the constant currency kind of equivalent?

Yeah. The delta would be similar.

The FX is a material impact in terms of how we translate earnings back into AUD from Southeast Asia. They are the entirety of the reason.

Typically, we would expect that region to grow, given the waiting to MedTech, sort of at high single digits on a sort of sustainable track. Underlying, that's what happened.

It may be helpful to maybe reference, outside of capital sales, we did continue to see low double-digit growth in our MedTech business. There isn't, again, there isn't anything fundamental, and that it is temporary.

I'm conscious, Adrian, the second part to the question is then why revenue 10% 10% up as well. We did mention at the half, we did have a—because it was a similar distortion at half 1, we did have a change in one of our contract logistics customers from 3PL to 4PL in the first half, which increased revenue, but not GOR or EBITDA.

That's distorted the margin. Again, that's a temporary factor, we should expect that to normalize as we go forward.

Thank you for that. Capital sales big swing on the comparative, particularly for the second half, and then in the revenues, a change in customer recognition 3PL to 4PL, and FX being the other bridge in that explanation.

Summarized, yes.

Good summary.

Okay. Just a second question, just staying in Medical Technologies.

It feels to me arithmetically the group returns there are more like 7%. When you think about you've spent $1.6 billion out of the $2 billion over the last 5 years, and the earnings number doesn't look like it's—yeah, I call it sort of 120-ish, 130-ish.

What is the license to kind of keep deploying money into that space? What sort of returns are you actually targeting from the bolt-ons?

How do you kind of lift the group returns against that kind of arithmetic starting point?

Fair question, Adrian. I think we'd go back to Investor Day, and we start with the tested calculation that we made around the return on capital deployed in M&A over the last, I believe it was 5 years, of 16%.

We're confident that the deployment of capital really creates value for the group there. What we're observing on the ground is I would say the critical mass that we're achieving in Southeast Asia, and the solutions that are coming to market in allographs.

The critical mass that we're hitting in Southeast Asia is we now have the backbone of a leadership position across the region, and we're seeing more and more that gives us access to franchise expansions. That means that sort of suppliers are choosing to come to us with their new products for the region.

Great example is actually Catalyst, where we had an existing relationship with that supplier in Australia. They were really pleased with the work that we've done for them there, and then we went through this acquisition, we've then extended that supply relationship throughout Southeast Asia, and we think we've got a lot more growth opportunities.

That's in terms of the MedTech distribution, sort of leveraging that growth position and that scale. Within allographs, we brought the Acellular Dermal Matrix to market.

We talked a bit about it at the Investor Day. It was a new approach, new solution to helping people with breast reconstruction.

That's caught on really well because it's got a tremendous impact on patient recovery. We keep getting drawn into more and more procedures, and so I think that will also continue to be a great opportunity for the group.

Really pleased with MedTech, and looking forward to more growth.

Just to hold you there, is the maths right? If you look at the capital employed to date, are you returning about 7% out of that vertical?

I think I have not had the opportunity to go back and look over the Lifehealthcare acquisition, which was over 5 years ago now. Was it in 2021?

That's right. I think, Adrian, what we have seen certainly in recent years is a continued improvement of the return on capital employed from the division, which speaks to, I guess, the organic growth potential, particularly of the markets in Southeast Asia, but also in the NZ, as well as the accretive bolt-on acquisitions, which, as we've talked about, both have synergistic value and provide access into further high-margin, high-growth geographies and therapy areas.

I think are we targeting a higher return on capital at the group? Absolutely.

We continue to be focused on driving towards 15% at the group, and MedTech will continue to increase as part of that.

Okay. If I summarize that, you sort of regard the establishment of MedTech, which is a sizeable amount of money, as a sort of a sunk investment, and the activities that you're doing now are quite accretive off that platform.

That's correct.

We certainly think it's accretive on the platform.

It certainly is accretive.

Hello, thank you for taking my questions. Firstly, can I ask—

Hi, Laura.

—can I ask if you've got any remaining inventory write-down or systems cutover left to do related to the DC program now that Kemps Creek is up and running? I'm thinking about the kind of tail work that you'd do to finish off the shutdown of the old pieces.

That's a great question, and I'm delighted that when we say the chapter's closed, the chapter's closed. All of the impact of the startup and inventory transition is captured within the FY26 results.

We wouldn't be expecting that to hit us in FY27. Laura, just for those who may not recognize your point, during the year, we were forced to run, for example, 2 facilities at the same time in parallel as we brought up Kemps Creek.

I believe that Laura is referring to the fact that that's a heavy load on us, but now that's behind us, and we're now putting them to work and getting the utilization up.

Great, that's very clear. Then my second question is in the community pharmacy setting, do you find that you're having to compete for patient spend on high-priced out-of-pocket drugs?

GLP-1s in the weight-loss setting would be the obvious example. Or do you just get the market share that you would expect without too much extra effort and the TerryWhite positioning as it is?

I think what we see is the GLP-1 space is fierce in the sense that it's a real flashpoint for competitive dynamics, and we probably indexed slightly low in GLP-1s in terms of our share. Still very respectable, but slightly less than what you might expect.

However, in high-value medicines, which are, of course, priced higher than GLP-1s, they're more than $1,000 a dose, that's where we probably tend to over-index in our share. That's again a result of the reliability of the Symbion network and the care focus of TerryWhite.

I think that's consistent with our positioning in the market.

Perfect, thanks very much. You're welcome.

Hi, Stephen.

Hi, it's actually Nick from Macquarie. Steve's just tied up on another call.

I was asking a couple of questions on his behalf. Firstly, just in terms of the first month of the new 1PBA, and the inclusion of the high-value medicines versus the sort of lower margins, on a net basis, where are you guys washing out

with that? That's a really great question.

In the first month of trading, we've seen 3 different factors at work. First is the, exactly as you say, the change in the tiering of medicines from 3 tiers to 4 tiers.

We've then seen increased or continued competitive dynamics. Offsetting that, we've then had the CSO come through.

Literally 1 month of trading. I think we'd say it's as expected and the impacts included in the guidance that we've provided for the year, but more data to come as that trading shakes out.

I think over time, moving from that 3-tier system to the 4-tier system is a net benefit for us, but in the short term, a little less so. Why do I say that?

Because the cap changes from $54 to $223. With the continued rise of high medicines and complex medicines, that will tend to work to our benefit in the Symbion division.

Great. Then just in terms of the CSO pool, are you guys still on track to capture the 29% share that you previously talked about of the funding uplift?

We're absolutely on track on a gross basis to capture 29% of the $78 million. Again, those 2 other factors that I've just called out: the offsetting impact in the short term of 3 tiers moving to 4 tiers, which is probably a mild headwind, and then of course continued competitive dynamics in the space.

As you pointed out, Nick, we're just in the first month. It's going to take a little while to settle in, but again, our best expectation contained in that guidance number we've provided.

Great, thank you.

Hi, Marcus.

Good morning, team. Just, Adam, I just wondered if you could be drawn a little bit more on maybe a divisional view on that guidance in terms of the relative growth rate.

Are you expecting in particular higher or lower than 5% in Healthcare?

If I go back to our 4 divisions, the expectation is bang on Investor Day. We'd expect slightly slower growth from Symbion and Healthcare Distribution, slightly higher growth from Retail Pharmacy Brands, Animal Care, and Medical Technology.

Again, the opportunities there are sort of real. They're accruing from our current leadership positions in each of those sectors, and so that's what gives us the confidence despite some of the cost pressures in front of us.

Great. I suppose you've mentioned competition a few times when it comes to Community Pharmacy.

Maybe if you could just elaborate a little bit in terms of is this sort of the rolling impact as you contract more and more of your third-party distributors, or maybe just a little bit more context in terms of how that competition's playing out at the moment?

Marcus, absolutely. Forgive me if I repeat what I think we've spoken about before, but the change of the single largest wholesale customer 2 years ago kicked off a period of market flux.

During that period, we also happened to see an increase in contract renewals during FY25. That really kicked off a period of competitive intensity.

I would say that competitive intensity accelerated and increased during FY25, but then I would say has stabilized—it hasn't reduced, but I'd say it stabilized—during FY26. We would expect that competitive intensity to continue during FY27, and that's what we've baked into the guidance.

A fair question, Marcus.

It's more of an annualization of where margins have got to or rebates, or as opposed to incremental reductions?

I'd say a little bit of both. I'd say because the average tenor length is in the region of 3 to 4 years.

You've got the annualization of the ones you refer to, but you've also got some new ones coming in at the more competitive rate.

Sure. Then secondly, if you call it a second question, I just wonder if you could give us a little bit of perspective into—yeah, well, might be 2 and a half.

Could you just give us a little bit of perspective in terms of where you saw market growth in the 2 big markets being Community and Hospital last year and and where you think market growth is going this year? I suppose market being, I suppose, overall level of spend in medicines.

Sure. I'm going to throw to Alistair in just a moment to speak to both of those in Community Pharmacy and in Hospital.

I'd say the thematic here is, of course, GLP-1s, but also high-value medicines. We're seeing the continued emergence of a couple of oncology blockbusters that continue to also be high value and making a difference in the market.

Alistair, what would you add to that?

That's certainly an important dynamic, which is obviously driving the growth. GLP-1s are still continue to grow quickly in dollar terms.

They're obviously beginning to cycle a higher base. We saw in the second half slightly slower high growth from GLP-1s, and I would expect that to continue unless there is a change in format for GLP-1s.

What I would say in addition to that, in Community Pharmacy, somewhat tied to my previous comment, we did see very high growth in FY25, and in particular in the second half, which grew revenue at 20%. There is some cycling impacts in '26, but I think as we look forward, I think the 2 drivers of growth will continue to be high-value medicines and GLP-1s.

Did we answer your question there, Marcus?

I suppose when you look at the PBS data in the last 5 months, the overall level of Section 85 medicine spend growth is zero. I take your point, there's a lot of growth in high value, but it does seem like there's other things offsetting it.

I'm not sure if you're necessarily seeing that, because obviously PBS data is not quite the full picture,

but

it does feel like the level of overall growth in medicines is starting to plateau.

I think on the PBS, that's absolutely right. Again, what we're seeing is in the high value, in the private scripts, in the GLP-1s, that's what's continuing to flow through for us.

Also that's probably thematically consistent with the continued rise of complex medicines and more advanced medicines that are coming ahead.

The only other point I'd sort of reiterate, Marcus, is that there is an element of cycling a very high growth rate in the second half and more broadly across FY25. I think it's as much about that as about the ongoing trajectory of growth in the industry.

It's just one to bear in mind, cycling a very high H2.

Sure. Does that count as 2 and a half, Marcus?

It's extension. You don't know off the top of your head what private script would be of your Community Pharmacy business in your Hospital business?

I think our expectations are contained in the guidance we provided, Marcus. I'll let you do that one.

No, what is the relative size of private script versus government-funded, just to give us a feel of the magnitude of what each of them contribute? Is it—

I think we won't be sharing that today, but I appreciate the theme,

and

we'll think about it for future discussion.

Thank you.

Oh, good morning. Thanks very much.

Just want to go back to the wholesale agreement again. I understand you talk about those 3 tiers there.

I think originally you were talking about the changes to mark-up and so forth across those tiers would be managed to be relatively neutral, and the CSO uplift would sort of come through as the benefit. Has it played out that way?

It's been 1 month of trading, Dan. Very fair question.

I would say it's been a mild negative on the change from the 3 tiers to the 4 tiers in that first month of trading. It is going to be an offset for us.

I think long-term, it's very helpful, but and again, it's 1 month and it's straight after the financial year-end, it's tough to get a comprehensive read that we think will continue. Certainly I think our bias would be a slight negative in the short term.

Understood. Just on that basis, and looking at the uplift in the CSO, which is pretty significant, it makes the underlying EBITDA growth you've guided to in FY27 look pretty modest, especially when you consider some of the acquisitions from last year that will contribute to that.

Are you implying that there's softness in the underlying business, or is that CSO benefit smaller than we're imagining?

I think you've mentioned tiering, which is absolutely fair, and one of the other callers mentioned the ongoing competitive challenges within Community Pharmacy. As we mentioned there, there's continued rollover of contracts into the new pricing regime, or softer pricing regime, as well as annualizing what's occurred before.

I think the net expression, we're very confident with the guidance, and that reflects both a slower growth in Symbion and Healthcare Distribution, but also great gains in the other divisions.

Okay. Thank you very much.

Thanks, Dan. Thank you.

Morning, guys. Just a quick one on the Symbion network.

Sort of you've helpfully given the utilization for contract logistics over in Australia. Where does utilization sit for the Symbion network in Australia?

Obviously, you've put a bit of capacity on that side of the business at the moment, and sort of how many years of growth do you need sort of to grow into that capacity, do you think?

Oh, that's a great question. Look, I'd be disappointed if we were busting at the seams having just finished, literally in the last half.

I think we've got a number of years of growth ahead of us. Also, I think there's 2 sort of layers to that.

One is just straight-up more rack space that we can deploy now, but also the sort of smaller and more efficient slugs of incremental capex if we want to re-rack or add more incremental capacity later on. I think we've got plenty of years of growth in front of us.

The focus today is productivity. Let's take the volume that we do have and pump it through as most efficiently as possible.

The 3 automated facilities that we have, Keysborough, Acacia Ridge, Kemps Creek, they account for the vast majority of our million doses a day that we supply to Australians. Every time that we can drive out productivity, that really impacts the labor cost base.

In Kemps Creek, I think we've set out the target of 30% productivity over Greystanes to be achieved by the year-end, and certainly the team are charging ahead on getting to that productivity.

Maybe just a second one on capex. You're pulling capex back quite a lot next year, sort of how much of that $100 million is sort of maintenance or ongoing capex versus how much is available for growth?

Sort of are you going to have to stick to that $100 million and turn away attractive growth projects if you get a lot of your divisions come to you with attractive investment opportunities well above your cost of capital hurdle and you're saying no? Is that how we should read it?

Ben, I'm not sure if one of the divisional CEOs got to you and has been asking you to ask me that question. Certainly, there's no shortage of great growth opportunities in front of us, but we are very disciplined about what's the return that they can provide.

In terms of the overall maintenance versus growth within the $100 million budget, I'd say a little more than half is connected to maintenance and safety, and so that leaves a healthy clip for growth opportunities. We won't be held back if there's an incremental opportunity to deploy capital to, I don't know, serve a customer.

It's interesting you mentioned it, Ben, because one of the divisions actually had an opportunity come up in the last month where a customer came to them with an urgent request for a little extra capital, but a very attractive contract extension, which we've done. Now, I've talked about capital in terms of capital expenditure, but of course the other thing that I think we're pleased about with the reduction in capex is it just gives us a little more room for bolt-on M&A as well.

Again, with that privileged access to deal flow, I think there's going to be some opportunities there that would be pretty interesting.

All good. Thank you.

That's all for me.

Thanks, Ben.

Thanks,

and

good morning, Adam and Alistair.

Good morning, Saul.

Hey, Saul.

Apologies if I missed this on the call, Adam, but was there any commentary you made around the outlook for the Chemist Warehouse New Zealand wholesaling contract?

Saul, very fair question. Let me mention again what we said at Investor Day.

We don't love commenting on individual contracts, but this one has been mentioned before. It's well understood that the contract is scheduled to roll off at the end of calendar '26, and the team have known that for a long time, and they're expected to redeploy or reduce the cost base to match changes in their contract base, including this contract.

Now, the 2 things probably to add. One is structurally, the New Zealand pharmacy wholesale market is significantly less attractive than the Australian pharmacy wholesale market.

It's a much lower margin base, the loss of any contract in New Zealand is less meaningful in terms of group-wide EBITDA. That probably helps to explain why the magnitude of this contract would be mid to high single-digit EBITDA million, 1% of group EBITDA.

The other thing to mention is, and maybe we haven't done a good job of really pointing this out, but our New Zealand colleagues have done a great job over the last few years of consolidating and modernizing the asset base. They absolutely are aware of commercial dynamics in New Zealand and have been tailoring our asset base to suit.

I think we're comfortable that, again, that contract is scheduled to roll off at the end of calendar '26, and that the team will deal with it appropriately. Does that give you a little bit more background on that one, Saul?

It does. Just a follow-up, the guidance that you've given for fiscal '27, does that assume half a year's worth of that contract, and then the second half it expires?

Is that how we should read that?

It certainly includes our best understanding of that contract for FY27. That's

all I had. Thanks.

Oh, thanks, Saul.

Thanks, Saul.

Hey, Tom.

G'day, Adam. Good morning, guys.

Thanks for taking my questions. I just had a quick one for Alistair, actually, just around the restructuring and transition costs taken below the line.

It looked like another $16 million in the second half. Now that we're through the DC renewal program, does that sort of go to zero into '27, or just any comments around the outlook for one-off costs and cash conversion into next year?

No, thanks for the question, Tom. As I mentioned on the call, the vast majority of the one-off costs or the restructuring and site transition costs at least were connected to the DC renewal program.

That has obviously now concluded, we wouldn't expect any other site-related transition costs associated with that program as we look forward. That and the reduction in capex will both support stronger cash flows as we look forward to FY27, which we're obviously pleased about because that provides further capacity and flexibility to invest in growth.

Looking forward to '27. Great,

that's all I had. Thanks, guys.

Thanks, Tom.

Thanks, Tom.

Thank you all for dialling in today. We really appreciate the time you've taken, and we also very much value the questions that have been asked.

Importantly, as you just heard Alistair mention, FY26 was an inflection year for EBOS. It's now behind us.

Looking forward, if you think that humans will continue to age and continue to love their pets, then the EBOS portfolio is well positioned to deliver this care productively and in partnerships with others. Thank you for your ongoing support, and we look forward to updating you on our progress throughout the year.